Research programme: Universal influenza vaccine - Sumitomo Pharma/National Istitute of Biomedical Innovation
Latest Information Update: 28 May 2024
At a glance
- Originator National Institute of Biomedical Innovation; Sumitomo Dainippon Pharma
- Developer National Institute of Biomedical Innovation; Sumitomo Pharma
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Japan (Parenteral)
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 24 Apr 2020 Sumitomo Dainippon Pharma concludes R&D agreement with National Institute of Biomedical Innovation